Benzinga | Aug 4, 2021 04:23PM EDT

Sarepta Therapeutics Q2 EPS $(1.52) Misses $(1.29) Estimate, Sales $141.80M Miss $162.64M Estimate

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(1.52) per share which missed the analyst consensus estimate of $(1.29) by 17.83 percent. This is a 0.66 percent decrease over losses of $(1.51) per share from the same period last year. The company reported quarterly sales of $141.80 million which missed the analyst consensus estimate of $162.64 million by 12.81 percent. This is a 3.23 percent increase over sales of $137.36 million the same period last year.